Submitted by Anonymous (not verified) on 31 July 2025 - 10:21
Human medicines European public assessment report (EPAR): Libmyris, adalimumab, Date of authorisation: 12/11/2021, Revision: 6, Status: Authorised
Source:
Human medicines European public assessment report (EPAR): Libmyris, adalimumab, Date of authorisation: 12/11/2021, Revision: 6, Status: Authorised